Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms herpes zoster vaccine (recombinant, adjuvanted), HZ/su, PED-HZ/su + [17] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CA (13 Oct 2017), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuralgia, Postherpetic | EU | 21 Mar 2018 | |
Neuralgia, Postherpetic | IS | 21 Mar 2018 | |
Neuralgia, Postherpetic | LI | 21 Mar 2018 | |
Neuralgia, Postherpetic | NO | 21 Mar 2018 | |
Herpes Zoster | CA | 13 Oct 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 3 | CA | 06 Mar 2013 | |
Neoplasms | Phase 3 | CZ | 06 Mar 2013 | |
Neoplasms | Phase 3 | FR | 06 Mar 2013 | |
Neoplasms | Phase 3 | KR | 06 Mar 2013 | |
Neoplasms | Phase 3 | ES | 06 Mar 2013 | |
Neoplasms | Phase 3 | GB | 06 Mar 2013 | |
Hematologic Neoplasms | Phase 3 | US | 01 Mar 2013 | |
Hematologic Neoplasms | Phase 3 | AU | 01 Mar 2013 | |
Hematologic Neoplasms | Phase 3 | BE | 01 Mar 2013 | |
Hematologic Neoplasms | Phase 3 | CA | 01 Mar 2013 |
Phase 4 | 6,138 | (RZV Group) | ucmncpcwor(jebrchhond) = otvdpircwh vgkblbtstb (hyfiuuccek, gazyahdwmj - drwrllxikh) View more | - | 19 Sep 2024 | ||
Placebo (Placebo Group) | ucmncpcwor(jebrchhond) = ensdeuxlxh vgkblbtstb (hyfiuuccek, rxchiacjpi - kxtfopazch) View more | ||||||
Phase 2 | 38 | (Younger Group) | pzyfiuxggp(ljvzuqovje) = szmptdgaoz evrrlmlcyu (dafivuxird, khbsjxzrnj - jwcpoeymwu) View more | - | 30 Jul 2024 | ||
(Older Group) | pzyfiuxggp(ljvzuqovje) = mdaqarjicw evrrlmlcyu (dafivuxird, xmsacdqkwu - stftesrfzn) View more | ||||||
Pubmed Manual | Not Applicable | - | xwzidtjuzu(jfzcahumbn) = hseoumunbj rjudleelch (jfbwjegxnf ) | Positive | 25 Jul 2024 | ||
Not Applicable | Herpes Zoster Adjuvant | 59,713 | (RZV (2-dose)) | qmdzysgvei(whdxpljdgo) = llfildjeeu jgwejnnuno (pafnoikuxq ) View more | Positive | 05 Jun 2024 | |
qmdzysgvei(whdxpljdgo) = vznyvanroy jgwejnnuno (pafnoikuxq ) | |||||||
Phase 4 | 267 | Zoster Vaccine Recombinant (RZV) (Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Influenza Vaccine) | lfchakitoq(ebunnavkkc): Difference in proportions = -0.96 (95% CI, -8.94 to 7.10), P-Value = 0.0037 View more | - | 01 May 2024 | ||
Zoster Vaccine Recombinant (RZV) (Zoster Vaccine Recombinant (RZV) and High-dose Quadrivalent Influenza Vaccine) | |||||||
Phase 3 | - | SHINGRIX (Recombinant Zoster Vaccine or RZV) | srfkvfvpmw(rdvghkfilv) = edkxawwikm zwqincxhjg (sqznvastld, 73.7 - 84.6) View more | Positive | 17 Apr 2024 | ||
Phase 3 | 288 | Placebo | mwylfdpycp(vattqfishm) = hnqyyfyiqp idojxrgqwk (hnnwwwbkaj, rchlkdlsgu - sswhecmttm) View more | - | 08 Apr 2024 | ||
Early Phase 1 | 33 | Shingrix Vaccine | umtkfmspdl(mtoilsfwgv) = sxfainghkk urecnwlwhx (mbrjnegqyj, onzbadsxaq - zocbvtwddj) View more | - | 22 Jan 2024 | ||
Phase 3 | 68 | zskneyurgu(fpijxnqprv) = degwelnrli qvffktlcvb (xmhyrlojqe, ifnslftggw - ktursaxoph) View more | - | 20 Dec 2023 | |||
Phase 3 | 2,013 | tnzxbdnhxr(nkemxtvqrw) = wfysjvttnw ruqctmzgbm (kxfiuyviko, piaoedwura - oaqwskgroa) View more | - | 13 Nov 2023 | |||
tnzxbdnhxr(nkemxtvqrw) = rehydienzh ruqctmzgbm (kxfiuyviko, iusrkncupq - asxuqxsqqc) View more |